Viz.ai partners with Sanofi, Regeneron for AI COPD solution

USA – Viz.ai has formed a multi-year partnership with pharmaceutical leaders Sanofi and Regeneron to develop and test an AI-powered solution that improves the clinical management of chronic obstructive pulmonary disease (COPD).

The collaboration deploys the Viz COPD module, a smart care coordination tool that uses artificial intelligence and electronic health records (EHR) to identify and manage high-risk COPD patients more effectively.

COPD, a widespread lung disease that restricts airflow and hampers breathing, requires early detection and consistent care for effective management.

The new module simplifies this process by using natural language processing to scan EHR data, follow clinical guidelines, and flag patients in need of urgent or specialized attention.

Viz.ai builds this innovation on its existing footprint in over 1,700 hospitals and health systems, where more than 60,000 providers already use its tools.

By integrating the COPD module into clinical workflows, the company aims to boost patient outcomes and improve care coordination, especially for those often overlooked due to late diagnoses or fragmented care.

Chris Mansi, Viz.ai’s co-founder and CEO, called the partnership a major step in the company’s mission to bring AI to high-need clinical areas.

“This collaboration with Sanofi and Regeneron helps us expand AI-driven care coordination in conditions like COPD,” he said.

“We’re working to equip healthcare professionals with smarter, data-driven tools that truly improve patient lives.”

Viz.ai’s machine learning tools, widely used across the U.S. and Europe, accelerate diagnosis and treatment by enhancing clinical efficiency.

Through its Viz.ai One platform, the company helps identify patients with various conditions, supports decision-making, and streamlines care, benefiting patients, providers, and industry stakeholders alike.